NeoTYPE Cancer Profiles

Size: px
Start display at page:

Download "NeoTYPE Cancer Profiles"

Transcription

1 NeoTYPE Cancer Profiles Multimethod Analysis of 25+ Hematologic Diseases and Solid Tumors Anatomic Pathology FISH Molecular The next generation of diagnostic, prognostic, and therapeutic assessment

2 NeoTYPE Cancer Profiles are multi-method test panels based on next-gen sequencing that identify the genetic changes most significant for Confirming diagnosis Disease classification Assessing prognosis Predicting response to therapy Identifying new therapeutic approaches Identifying clinical trial opportunities When to test These Profiles highlight high-frequency recurrent mutations and provide a practical approach to understanding the cancer s biology for the most effective patient management. Tests are appropriate for: First-line gene testing Patients with an unusual clinical presentation Developing therapeutic strategies Identifying clinical trials Patients resistant to conventional therapy 2 NeoGenomics Laboratories

3 Benefits and Advantages of Targeted Profile Testing Targeted Test design is tailored to driver mutations in specific tumors. Actionable All genes have clinical significance when mutated. Comprehensive Unique reporting of diagnostic, prognostic, and therapeutic implications. Flexible Choose as-shown or as add on. Efficient With fast TAT s, NeoTYPEs can replace first-line single-gene testing. Quantitative Reporting of mutant allele frequencies is useful for monitoring. Cost-effective Flexibility, Performance, Selection Next-generation sequencing (NGS) is widely known for its high sensitivity which aids detection of abnormalities in small biopsies, minimal residual disease, and subclonal heterogeneity. The NeoTYPE next-gen suite offers an additional set of distinct benefits focusing on driver genes and actionable abnormalities, which includes point mutations, indels, translocations, and more. NeoTYPE Cancer Profiles simplify the laboratory testing process and provide key diagnostic, prognostic, and predictive information you need for up-to-date and fully informed decision-making. NeoGenomics Laboratories 3

4 Sa m pl e Sample Report 4 NeoGenomics Laboratories

5 Broad Reach Hematologic Profiles Myeloid Disorders (54 Molecular) ABL1 ASXL1 ATRX BCOR BCORL1 CALR CBL CBLB CBLC CDKN2A CSF3R CUX1 DNMT3A ETV6 EZH2 FBXW7 GATA1 GATA2 GNAS IKZF1 JAK2 V617F JAK2 Exon KDM6A MLL MPL MYD88 PHF6 RAD21 RUNX1 SF3B1 SMC1A SMC3 SRSF2 STAG2 TET2 U2AF1 WT1 ZRSR2 Broad Reach Solid Tumor Profiles Precision (48 Molecular, 1 IHC) ABL1 ALK APC ATM CDH1 CDKN2A CSF1R FBXW7 GNA11 GNAQ GNAS HNF1A JAK2 KDR MLH1 MPL RB1 RET SMARCB1 STK11 VHL Discovery (315 Molecular, 9 FISH, 1 IHC) Next-gen sequencing of 315 genes + 9 FISH +. This is an actionable discovery panel suitable for clinical research applications and widespectrum patient testing. See website or handout for complete test details. Cancer Exome (4813 Molecular) Next-gen sequencing of 4813 cancer-related genes. Testing is recommended for those interested in academic or clinical research. See website for complete test details, or call our Client Services Team at Cancer-Specific Hematologic Profiles AITL/Peripheral T-Cell Lymphoma Profile (5 Molecular) DNMT3A RHOA TET2 AML Favorable-Risk (2 Molecular) AML Prognostic (27 Molecular) ASXL1 BCOR CSF3R DNMT3A ETV6 EZH2 JAK2 MLL PHF6 RUNX1 STAG2 TET2 WT1 CLL Prognostic (5 Molecular, 1 FISH Panel) IgVH Mutation MYD88 SF3B1 CLL FISH Panel JMML (16 Molecular) CBL JAK2 V617F JAK2 Exon Lymphoma (8 Molecular) BCL1 BCL2 CARD11 CD79B EZH2 MYD88 MDS/CMML (32 Molecular) ASXL1 BCOR BCORL1 CBL CUX1 DNMT3A ETV6 EZH2 JAK2 V617F JAK2 Exon RUNX1 SF3B1 SRSF2 STAG2 TET2 U2AF1 ZRSR2 MPN (25 Molecular) ABL1 ASXL1 CALR CSF3R EZH2 JAK2 V617F JAK2 Exon MPL SRSF2 TET2 U2AF1 NeoGenomics Laboratories 5

6 Cancer-Specific Solid Tumor Profiles Brain (22 Molecular, 5 FISH, 1 IHC) ATRX vlll Analysis MGMT Promoter Methylation TERT Promoter 1p/19q Deletion FISH FISH FISH MYCN FISH FISH Breast (22 Molecular, 3 FISH, 1 IHC) BRCA1 BRCA2 FISH FISH Cervical (22 Molecular, 2 FISH, 1 IHC) FISH FISH Colorectal (24 Molecular, 2 FISH, 1 IHC) APC Microsatellite Instability (MSI) MLH1 Promoter Methylation FISH FISH Endometrial (21 Molecular, 2 FISH, 1 IHC) Microsatellite Instability (MSI) FISH FISH Esophageal (22 Molecular, 3 FISH, 1 IHC) FISH FISH Gastric (22 Molecular, 3 FISH, 1 IHC) FISH FISH GIST (11 Molecular, 1 IHC) Head & Neck (25 Molecular, 2 FISH, 1 IHC) ATM CDKN2A RB FISH FISH HPV DNA Tissue Test Liver/Biliary (24 Molecular, 2 FISH, 1 IHC) ATM CDKN2A FISH FISH Liposarcoma Fusion Profile (5 Molecular, 1 FISH) COL1A2-PLAG1 EWSR1-DDIT3 FUS-DDIT3 HMGA2-LPP LPP-HMGA2 MDM2 FISH NeoGenomics Laboratories 6

7 Lung (21 Molecular, 6 FISH, 1 IHC) Exon 14 Deletion Analysis ALK FISH FISH FISH RET FISH ROS1 FISH Melanoma (17 Molecular, 1 FISH, 1 IHC) GNAQ TERT Promoter FISH Other Solid Tumor (24 Molecular, 2 FISH, 1 IHC) GNAS FISH FISH Ovarian (22 Molecular, 2 FISH, 1 IHC) BRCA1 BRCA2 FISH FISH Pancreas (22 Molecular, 3 FISH, 1 IHC) BRCA1 BRCA2 FISH FISH Soft Tissue (19 Molecular, 2 FISH, 1 IHC) GNAS FISH FISH Thyroid (16 Molecular, 2 FISH, 1 IHC) ALK RET TERT Promoter FISH RET FISH Options for Customization Add-Ons Any genes in the 54-gene Myeloid Disorders Profile may be added to any of the Hematologic Diseases Profiles. Any genes in the 48-gene Precision Profile for Solid Tumors may be added to any of the other Solid Tumor Profiles. Results of testing for added genes will be included in the comprehensive NeoTYPE report for that Profile. Tech-Only FISH This option is available to pathology clients who want to perform the professional components of any FISH tests within a Profile. These clients should order the component FISH tests as tech-only in combination with the molecular portion of the Profile. NeoGenomics Laboratories 7

8 Ordering Information Specimen options: Peripheral blood Bone marrow aspirate Fresh tissue FFPE slides or block TAT: days (varies by Profile) Billing: NeoGenomics offers institutional and third-party billing. New tests are in development. Sign up at to be notified. NeoGenomics Laboratories is a specialized oncology reference laboratory providing the latest technologies, testing partnership opportunities, and interactive education to the oncology and pathology communities. We offer the complete spectrum of diagnostic services in molecular testing, FISH, cytogenetics, flow cytometry, and immunohistochemistry through our nation-wide network of CAP-accredited, CLIA-approved laboratories. Committed to research as the means to improve patient care, we provide Pharma Services for pharmaceutical companies, in vitro diagnostic manufacturers, and academic scientist-clinicians. We promote joint publication with our client physicians. NeoGenomics welcomes your inquiries for collaborations. Please contact us for more information Commonwealth Dr., Suite 9 Fort Myers, FL Phone: / Fax: neogenomics.com 2017 NeoGenomics Laboratories, Inc. All Rights Reserved. All other trademarks are the property of their respective owners. Rev

NeoTYPE Cancer Profiles

NeoTYPE Cancer Profiles NeoTYPE Cancer Profiles 30+ Multimethod Assays for Hematologic Diseases and Solid Tumors Molecular FISH Anatomic Pathology The next generation of diagnostic, prognostic, and therapeutic assessment What

More information

Molecular. Oncology & Pathology. Diagnostic, Prognostic, Therapeutic, and Predisposition Tests in Precision Medicine. Liquid Biopsy.

Molecular. Oncology & Pathology. Diagnostic, Prognostic, Therapeutic, and Predisposition Tests in Precision Medicine. Liquid Biopsy. Molecular Oncology & Pathology Hereditary Cancer Somatic Cancer Liquid Biopsy Next-Gen Sequencing qpcr Sanger Sequencing Diagnostic, Prognostic, Therapeutic, and Predisposition Tests in Precision Medicine

More information

Out-Patient Billing CPT Codes

Out-Patient Billing CPT Codes Out-Patient Billing CPT Codes Updated Date: August 3, 08 Client Billed Molecular Tests HPV DNA Tissue Testing 8764 No Medicare Billed - Molecular Tests NeoARRAY NeoARRAY SNP/Cytogenetic No 89 NeoLAB NeoLAB

More information

August 17, Dear Valued Client:

August 17, Dear Valued Client: August 7, 08 Re: CMS Announces 6-Month Period of Enforcement Discretion for Laboratory Date of Service Exception Policy Under the Medicare Clinical Laboratory Fee Schedule (the 4 Day Rule ) Dear Valued

More information

Illumina Trusight Myeloid Panel validation A R FHAN R A FIQ

Illumina Trusight Myeloid Panel validation A R FHAN R A FIQ Illumina Trusight Myeloid Panel validation A R FHAN R A FIQ G E NETIC T E CHNOLOGIST MEDICAL G E NETICS, CARDIFF To Cover Background to the project Choice of panel Validation process Genes on panel, Protocol

More information

The Center for PERSONALIZED DIAGNOSTICS

The Center for PERSONALIZED DIAGNOSTICS The Center for PERSONALIZED DIAGNOSTICS Precision Diagnostics for Personalized Medicine A joint initiative between The Department of Pathology and Laboratory Medicine & The Abramson Cancer Center The (CPD)

More information

Pediatric Oncology & Pathology Services

Pediatric Oncology & Pathology Services Pediatric Oncology & Pathology Services Anatomic Pathology Flow Cytometry Cytogenetics Pharma Services Diagnostic, Prognostic, Predictive, and Predisposition Testing Pediatric Oncology & Pathology Services

More information

Next Generation Sequencing in Haematological Malignancy: A European Perspective. Wolfgang Kern, Munich Leukemia Laboratory

Next Generation Sequencing in Haematological Malignancy: A European Perspective. Wolfgang Kern, Munich Leukemia Laboratory Next Generation Sequencing in Haematological Malignancy: A European Perspective Wolfgang Kern, Munich Leukemia Laboratory Diagnostic Methods Cytomorphology Cytogenetics Immunophenotype Histology FISH Molecular

More information

Patricia Aoun MD, MPH Professor and Vice-Chair for Clinical Affairs Medical Director, Clinical Laboratories Department of Pathology City of Hope

Patricia Aoun MD, MPH Professor and Vice-Chair for Clinical Affairs Medical Director, Clinical Laboratories Department of Pathology City of Hope Patricia Aoun MD, MPH Professor and Vice-Chair for Clinical Affairs Medical Director, Clinical Laboratories Department of Pathology City of Hope National Medical Center Disclosures I have no disclosures

More information

Targeted Agent and Profiling Utilization Registry (TAPUR ) Study. February 2018

Targeted Agent and Profiling Utilization Registry (TAPUR ) Study. February 2018 Targeted Agent and Profiling Utilization Registry (TAPUR ) Study February 2018 Precision Medicine Therapies designed to target the molecular alteration that aids cancer development 30 TARGET gene alterations

More information

Blastic Plasmacytoid Dendritic Cell Neoplasm with DNMT3A and TET2 mutations (SH )

Blastic Plasmacytoid Dendritic Cell Neoplasm with DNMT3A and TET2 mutations (SH ) Blastic Plasmacytoid Dendritic Cell Neoplasm with DNMT3A and TET2 mutations (SH2017-0314) Habibe Kurt, Joseph D. Khoury, Carlos E. Bueso-Ramos, Jeffrey L. Jorgensen, Guilin Tang, L. Jeffrey Medeiros, and

More information

Laboratory Service Report

Laboratory Service Report Client C7028846-DLP Rochester Rochester, N 55901 Specimen Type Peripheral blood CR PDF Report available at: https://test.mmlaccess.com/reports/c7028846-zwselwql7p.ashx Indication for Test DS CR Pathogenic

More information

SureSelect Cancer All-In-One Custom and Catalog NGS Assays

SureSelect Cancer All-In-One Custom and Catalog NGS Assays SureSelect Cancer All-In-One Custom and Catalog NGS Assays Detect all cancer-relevant variants in a single SureSelect assay SNV Indel TL SNV Indel TL Single DNA input Single AIO assay Single data analysis

More information

TEST MENU TEST CPT CODES TAT. Chromosome Analysis Bone Marrow x 2, 88264, x 3, Days

TEST MENU TEST CPT CODES TAT. Chromosome Analysis Bone Marrow x 2, 88264, x 3, Days TEST MENU CANCER/LEUKEMIA CHROMOSOME ANALYSIS Chromosome Analysis Bone Marrow 88237 x 2, 88264, 88280 x 3, 88291 4 Days Chromosome Analysis Bone Marrow Core 88237 x 2, 88264, 88280 x 3, 88291 4 Days Chromosome

More information

IntelliGENSM. Integrated Oncology is making next generation sequencing faster and more accessible to the oncology community.

IntelliGENSM. Integrated Oncology is making next generation sequencing faster and more accessible to the oncology community. IntelliGENSM Integrated Oncology is making next generation sequencing faster and more accessible to the oncology community. NGS TRANSFORMS GENOMIC TESTING Background Cancers may emerge as a result of somatically

More information

Click to edit Master /tle style

Click to edit Master /tle style Click to edit Master /tle style Tel: (314) 747-7337 Toll Free: (866) 450-7697 Fax: (314) 747-7336 Email: gps@wustl.edu Website: gps.wustl.edu GENETIC TESTING IN CANCER Ka/nka Vigh-Conrad, PhD Genomics

More information

Supplementary Information

Supplementary Information Supplementary Information Table of Contents Supplementary methods... 2 Figure S1 - Variable DNA yield proportional to bone marrow aspirate cellularity.... 3 Figure S2 - Mutations by clinical ontogeny group....

More information

The preclinical efficacy of a novel telomerase inhibitor, imetelstat, in AML: A randomized trial in patient-derived xenografts

The preclinical efficacy of a novel telomerase inhibitor, imetelstat, in AML: A randomized trial in patient-derived xenografts The preclinical efficacy of a novel telomerase inhibitor, imetelstat, in AML: A randomized trial in patient-derived xenografts Claudia Bruedigam, Ph.D Gordon and Jessie Gilmour Leukaemia Research Laboratory

More information

Examining Genetics and Genomics of Acute Myeloid Leukemia in 2017

Examining Genetics and Genomics of Acute Myeloid Leukemia in 2017 Examining Genetics and Genomics of Acute Myeloid Leukemia in 2017 Elli Papaemmanuil, PhD Memorial Sloan Kettering Cancer Center New York, New York, United States Today s Talk Cancer genome introduction

More information

Clinical Grade Genomic Profiling: The Time Has Come

Clinical Grade Genomic Profiling: The Time Has Come Clinical Grade Genomic Profiling: The Time Has Come Gary Palmer, MD, JD, MBA, MPH Senior Vice President, Medical Affairs Foundation Medicine, Inc. Oct. 22, 2013 1 Why We Are Here A Shared Vision At Foundation

More information

Genomic Medicine: What every pathologist needs to know

Genomic Medicine: What every pathologist needs to know Genomic Medicine: What every pathologist needs to know Stephen P. Ethier, Ph.D. Professor, Department of Pathology and Laboratory Medicine, MUSC Director, MUSC Center for Genomic Medicine Genomics and

More information

Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK

Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK Haematopathology and Oncology Diagnostic Services (HODS) Addenbrookes Hospital Hills Road Cambridge CB2 0QQ Contact: Brian Warner Tel: +44

More information

Predictive biomarker profiling of > 1,900 sarcomas: Identification of potential novel treatment modalities

Predictive biomarker profiling of > 1,900 sarcomas: Identification of potential novel treatment modalities Predictive biomarker profiling of > 1,900 sarcomas: Identification of potential novel treatment modalities Sujana Movva 1, Wenhsiang Wen 2, Wangjuh Chen 2, Sherri Z. Millis 2, Margaret von Mehren 1, Zoran

More information

Next Generation Sequencing in Clinical Practice: Impact on Therapeutic Decision Making

Next Generation Sequencing in Clinical Practice: Impact on Therapeutic Decision Making Next Generation Sequencing in Clinical Practice: Impact on Therapeutic Decision Making November 20, 2014 Capturing Value in Next Generation Sequencing Symposium Douglas Johnson MD, MSCI Vanderbilt-Ingram

More information

Precision Oncology: Experience at UW

Precision Oncology: Experience at UW Precision Oncology: Experience at UW Colin Pritchard MD, PhD University of Washington, Department of Lab Medicine WSMOS Meeting November 1, 2013 Conflict of Interest Disclosures I declare the following,

More information

molecular oncology services

molecular oncology services Molecular Oncology molecular oncology services ATIENTS.ANSWERS.RESULTS. www.aruplab.com/oncology MARCH 2018 Information in this brochure is current as of March 2018. All content is subject to change. lease

More information

Please Silence Your Cell Phones. Thank You

Please Silence Your Cell Phones. Thank You Please Silence Your Cell Phones Thank You Utility of NGS and Comprehensive Genomic Profiling in Hematopathology Practice Maria E. Arcila M.D. Memorial Sloan Kettering Cancer Center New York, NY Disclosure

More information

Your single-source laboratory solution. FISH Probe Library

Your single-source laboratory solution. FISH Probe Library Your single-source laboratory solution. FISH Probe Library Alphabetical List by Probe with Clinical Indication Probe Clinical Indication 1p36 (TP73)/19q13 (GLTSCR) 1q21 (CKS1B) 5q (CSF1R/RPS14) 7q (MDFIC)

More information

Introduction of an NGS gene panel into the Haemato-Oncology MPN service

Introduction of an NGS gene panel into the Haemato-Oncology MPN service Introduction of an NGS gene panel into the Haemato-Oncology MPN service Dr. Anna Skowronska, Dr Jane Bryon, Dr Samuel Clokie, Dr Yvonne Wallis and Professor Mike Griffiths West Midlands Regional Genetics

More information

Laboratory Service Report

Laboratory Service Report Specimen Type Peripheral blood CR PDF Report available at: https://test.mmlaccess.com/reports/c7028846-ih2xuglwpq.ashx Indication for Test DS CR Pathogenic utations Detected CR 1. JAK2: c.1849g>t;p.val617phe

More information

Illumina s Cancer Research Portfolio and Dedicated Workflows

Illumina s Cancer Research Portfolio and Dedicated Workflows Illumina s Cancer Research Portfolio and Dedicated Workflows Michael Sohn Clinical Sales Specialist Spain&Italy 2017 2017 Illumina, Inc. All rights reserved. Illumina, 24sure, BaseSpace, BeadArray, BlueFish,

More information

Diagnostic application of SNParrays to brain cancers

Diagnostic application of SNParrays to brain cancers Diagnostic application of SNParrays to brain cancers Adriana Olar 4/17/2018 No disclosures 55 yo M, focal motor seizure T2 T1-post C DIAGNOSIS BRAIN, LEFT FRONTAL LOBE, BIOPSY: - DIFFUSE GLIOMA, OLIGODENDROGLIAL

More information

Supplementary Figure 1

Supplementary Figure 1 Count Count Supplementary Figure 1 Coverage per amplicon for error-corrected sequencing experiments. Errorcorrected consensus sequence (ECCS) coverage was calculated for each of the 568 amplicons in the

More information

Should Mutational Status in Primary Myelofibrosis (PMF) Guide Therapy..YES!!!

Should Mutational Status in Primary Myelofibrosis (PMF) Guide Therapy..YES!!! Should Mutational Status in Primary Myelofibrosis (PMF) Guide Therapy..YES!!! Lindsay Anne Magura Rein, MD Division of Hematologic Malignancies and Cellular Therapy/BMT A Little Bit of History.. 1665 Advanced

More information

Jennifer Hauenstein Oncology Cytogenetics Emory University Hospital Atlanta, GA

Jennifer Hauenstein Oncology Cytogenetics Emory University Hospital Atlanta, GA Comparison of Genomic Coverage using Affymetrix OncoScan Array and Illumina TruSight Tumor 170 NGS Panel for Detection of Copy Number Abnormalities in Clinical GBM Specimens Jennifer Hauenstein Oncology

More information

Molecular Testing Updates. Karen Rasmussen, PhD, FACMG Clinical Molecular Genetics Spectrum Medical Group, Pathology Division Portland, Maine

Molecular Testing Updates. Karen Rasmussen, PhD, FACMG Clinical Molecular Genetics Spectrum Medical Group, Pathology Division Portland, Maine Molecular Testing Updates Karen Rasmussen, PhD, FACMG Clinical Molecular Genetics Spectrum Medical Group, Pathology Division Portland, Maine Keeping Up with Predictive Molecular Testing in Oncology: Technical

More information

Dr David Guttery Senior PDRA Dept. of Cancer Studies and CRUK Leicester Centre University of Leicester

Dr David Guttery Senior PDRA Dept. of Cancer Studies and CRUK Leicester Centre University of Leicester Dr David Guttery Senior PDRA Dept. of Cancer Studies and CRUK Leicester Centre University of Leicester dsg6@le.ac.uk CFDNA/CTDNA Circulating-free AS A LIQUID DNA BIOPSY (cfdna) Tumour Biopsy Liquid Biopsy

More information

Clinical Grade Biomarkers in the Genomic Era Observations & Challenges

Clinical Grade Biomarkers in the Genomic Era Observations & Challenges Clinical Grade Biomarkers in the Genomic Era Observations & Challenges IOM Committee on Policy Issues in the Clinical Development & Use of Biomarkers for Molecularly Targeted Therapies March 31-April 1,

More information

APPLICATIONS OF NEXT GENERATION SEQUENCING IN SOLID TUMORS - PATHOLOGIST PROSPECTIVE

APPLICATIONS OF NEXT GENERATION SEQUENCING IN SOLID TUMORS - PATHOLOGIST PROSPECTIVE AMP COMPANION MEETING SYMPOSIUM AT USCAP 2015 NEXT-GENERATION OF PATHOLOGY: ROLE OF PATHOLOGIST IN NGS-BASED PERSONALIZED MEDICINE APPLICATIONS OF NEXT GENERATION SEQUENCING IN SOLID TUMORS - PATHOLOGIST

More information

Fluxion Biosciences and Swift Biosciences Somatic variant detection from liquid biopsy samples using targeted NGS

Fluxion Biosciences and Swift Biosciences Somatic variant detection from liquid biopsy samples using targeted NGS APPLICATION NOTE Fluxion Biosciences and Swift Biosciences OVERVIEW This application note describes a robust method for detecting somatic mutations from liquid biopsy samples by combining circulating tumor

More information

CentoCancer STRIVE FOR THE MOST COMPLETE INFORMATION

CentoCancer STRIVE FOR THE MOST COMPLETE INFORMATION CentoCancer STRIVE FOR THE MOST COMPLETE INFORMATION CentoCancer our most comprehensive oncogenetics panel for hereditary mutations Hereditary pathogenic variants confer an increased risk of developing

More information

The Next Generation in Cancer Diagnostics.

The Next Generation in Cancer Diagnostics. The Next Generation in Cancer Diagnostics. OncoTarget was created specifically for cancer patients. Every patient s cancer is unique, which is why discovering what makes it unique can be essential for

More information

Accel-Amplicon Panels

Accel-Amplicon Panels Accel-Amplicon Panels Amplicon sequencing has emerged as a reliable, cost-effective method for ultra-deep targeted sequencing. This highly adaptable approach is especially applicable for in-depth interrogation

More information

ADRL Advanced Diagnostics Research Laboratory

ADRL Advanced Diagnostics Research Laboratory ADRL Advanced Diagnostics Research Laboratory John DeCoteau, MD FRCP Department of Pathology, Division of Hematopathology University of Saskatchewan Saskatchewan Cancer Agency ADRL Project Objectives New

More information

Management of Myelodysplastic Syndromes

Management of Myelodysplastic Syndromes Management of Myelodysplastic Syndromes Peter L. Greenberg, MD Stanford Cancer Institute Myelodysplastic Syndromes: Clinical & Molecular Advances for Disease Classification and Prognostication MDSs: A

More information

West Midlands Regional Genetics Laboratory

West Midlands Regional Genetics Laboratory West Midlands Regional Genetics Laboratory Haemato-oncology service update letter October 2017 Dear colleagues, We are writing to outline the latest developments to our service, aiming to support the management

More information

The Evolving Role of Transplantation for MPN

The Evolving Role of Transplantation for MPN The Evolving Role of Transplantation for MPN (PMF, PV, ET) H.Joachim Deeg MD Fred Hutchinson Cancer Research Center, University of Washington, Seattle WA, SCCA jdeeg@fhcrc.org 10 th J. Niblack Conference

More information

Next generation histopathological diagnosis for precision medicine in solid cancers

Next generation histopathological diagnosis for precision medicine in solid cancers Next generation histopathological diagnosis for precision medicine in solid cancers from genomics to clinical application Aldo Scarpa ARC-NET Applied Research on Cancer Department of Pathology and Diagnostics

More information

Published Ahead of Print on April 14, 2016, as doi: /haematol Copyright 2016 Ferrata Storti Foundation.

Published Ahead of Print on April 14, 2016, as doi: /haematol Copyright 2016 Ferrata Storti Foundation. Published Ahead of Print on April 14, 2016, as doi:10.3324/haematol.2016.143214. Copyright 2016 Ferrata Storti Foundation. Immunohistochemical pattern of p53 is a measure of TP53 mutation burden and adverse

More information

Identification and clinical detection of genetic alterations of pre-neoplastic lesions Time for the PML ome? David Sidransky MD Johns Hopkins

Identification and clinical detection of genetic alterations of pre-neoplastic lesions Time for the PML ome? David Sidransky MD Johns Hopkins Identification and clinical detection of genetic alterations of pre-neoplastic lesions Time for the PML ome? David Sidransky MD Johns Hopkins February 3-5, 2016 Lansdowne Resort, Leesburg, VA Molecular

More information

Clinically Useful Next Generation Sequencing and Molecular Testing in Gliomas MacLean P. Nasrallah, MD PhD

Clinically Useful Next Generation Sequencing and Molecular Testing in Gliomas MacLean P. Nasrallah, MD PhD Clinically Useful Next Generation Sequencing and Molecular Testing in Gliomas MacLean P. Nasrallah, MD PhD Neuropathology Fellow Division of Neuropathology Center for Personalized Diagnosis (CPD) Glial

More information

Next generation sequencing analysis - A UK perspective. Nicholas Lea

Next generation sequencing analysis - A UK perspective. Nicholas Lea Next generation sequencing analysis - A UK perspective Nicholas Lea King s HMDC LMH is part of an integrated pathology service at King s Haematological Malignancy Diagnostic Centre (HMDC) HMDC serves population

More information

Enhancing Assessment of Myeloid Disorders in the Era of Precision Medicine

Enhancing Assessment of Myeloid Disorders in the Era of Precision Medicine Enhancing Assessment of Myeloid Disorders in the Era of Precision Medicine Michelle Afkhami, M.D. Medical Director, Clinical Molecular Diagnostic Laboratory City of Hope National Medical Center Objectives

More information

Enhancing Assessment of Myeloid Leukemia in the Era of Precision Medicine

Enhancing Assessment of Myeloid Leukemia in the Era of Precision Medicine Enhancing Assessment of Myeloid Leukemia in the Era of Precision Medicine Michelle Afkhami, M.D. Medical Director, Clinical Molecular Diagnostic Laboratory City of Hope National Medical Center How the

More information

Molecular Advances in Hematopathology

Molecular Advances in Hematopathology Molecular Advances in Hematopathology HOW MOLECULAR METHODS HAVE CHANGED MY PRACTICE Objectives Understand the importance of cytogenetic/molecular studies in hematolymphoid diseases Know some of the important

More information

Precision Medicine and Molecular Testing.

Precision Medicine and Molecular Testing. Precision Medicine and Molecular Testing. David A. Sallman, MD Assistant Member Department of Malignant Hematology Moffitt Cancer Center david.sallman@moffitt.org Disclosures Research funding for Celgene

More information

PDX Tumor Biology Pla0orms for Drug Advancement Neal Goodwin, Ph.D. Vice President Corporate Research & Development

PDX Tumor Biology Pla0orms for Drug Advancement Neal Goodwin, Ph.D. Vice President Corporate Research & Development PDX Tumor Biology Pla0orms for Drug Advancement Neal Goodwin, Ph.D. Vice President Corporate Research & Development ngoodwin@championsoncology.com +1-530-392-2741 Champions Oncology: Global provider of

More information

Enhancing Assessment of Myeloid Leukemia in the Era of Precision Medicine

Enhancing Assessment of Myeloid Leukemia in the Era of Precision Medicine Enhancing Assessment of Myeloid Leukemia in the Era of Precision Medicine Michelle Afkhami, M.D. Medical Director, Clinical Molecular Diagnostic Laboratory City of Hope National Medical Center How the

More information

Changing the Culture of Cancer Care II. Eric Holland Fred Hutchinson Cancer Research Center University of Washington Seattle

Changing the Culture of Cancer Care II. Eric Holland Fred Hutchinson Cancer Research Center University of Washington Seattle Changing the Culture of Cancer Care II Eric Holland Fred Hutchinson Cancer Research Center University of Washington Seattle Transforming Cancer Therapy Eric Holland Fred Hutchinson Cancer Research Center

More information

Overview. Methods 9/11/2017. Next Generation Sequencing and Precision Medicine in Hematological Malignancies. Genotyping in hematology

Overview. Methods 9/11/2017. Next Generation Sequencing and Precision Medicine in Hematological Malignancies. Genotyping in hematology Overview Next Generation Sequencing and Precision Medicine in Hematological Malignancies Sharathkumar Bhagavathi, MD University of Iowa Carver College of Medicine NGS as a genotyping platform in hematopathology

More information

Current and future applications of Molecular Pathology. Kathy Walsh Clinical Scientist NHS Lothian

Current and future applications of Molecular Pathology. Kathy Walsh Clinical Scientist NHS Lothian Current and future applications of Molecular Pathology Kathy Walsh Clinical Scientist NHS Lothian Molecular Pathology in Solid tumours Cancer type Genes tested Purpose Associated treatments Non small cell

More information

Personalised cancer care Information for Medical Specialists. A new way to unlock treatment options for your patients

Personalised cancer care Information for Medical Specialists. A new way to unlock treatment options for your patients Personalised cancer care Information for Medical Specialists A new way to unlock treatment options for your patients Contents Optimised for clinical benefit 4 Development history 4 Full FIND IT panel vs

More information

Select analysis on the next pages. Sample request and sending address see last page. Institut für Pathologie und Molekularpathologie

Select analysis on the next pages. Sample request and sending address see last page. Institut für Pathologie und Molekularpathologie Diagnostic Tumor Genome Analysis Schmelzbergstrasse 12 8091 Zürich Tel.: (+41) 044 255 3929 Fax.: (+41) 044 255 4416 Client (address, telephone number): ngs.pathologie@usz.ch www.pathologie.usz.ch Sample-Nr:

More information

Assessing the Economics of Genomic Medicine. Kenneth Offit, MD MPH Chief, Clinical Genetics Service Memorial Sloan-Kettering Cancer Center

Assessing the Economics of Genomic Medicine. Kenneth Offit, MD MPH Chief, Clinical Genetics Service Memorial Sloan-Kettering Cancer Center Assessing the Economics of Genomic Medicine Kenneth Offit, MD MPH Chief, Clinical Genetics Service Memorial Sloan-Kettering Cancer Center DISCLOSURES No conflicts Patents unenforced Consultancies unpaid

More information

Juan Ma 1, Jennifer Dunlap 2, Lisong Shen 1, Guang Fan 2 1

Juan Ma 1, Jennifer Dunlap 2, Lisong Shen 1, Guang Fan 2 1 Juan Ma 1, Jennifer Dunlap 2, Lisong Shen 1, Guang Fan 2 1 Xin Hua Hospital, Shanghai, China 2 Oregon Health & Science University, Portland, OR, United States AML is a hematopoietic neoplasms characterized

More information

The Challenges of Precision Medicine: New Advances in Molecular Diagnostic Testing- Impact for Healthcare

The Challenges of Precision Medicine: New Advances in Molecular Diagnostic Testing- Impact for Healthcare The Challenges of Precision Medicine: New Advances in Molecular Diagnostic Testing- Impact for Healthcare Jessica Wang-Rodriguez, MD Chief, VISN22 Consolidated Pathology and Laboratory Medicine Services

More information

EBUS-TBNA Diagnosis and Staging of Lung Cancer

EBUS-TBNA Diagnosis and Staging of Lung Cancer EBUS-TBNA Diagnosis and Staging of Lung Cancer Nirag Jhala MD, MIAC Professor of Pathology and Lab Med. Director of Anatomic Pathology and Cytopathology Lewis Katz School of Medicine@ Temple University

More information

Jocelyn Chapman, MD Division of Gynecologic Oncology. Julie S. Mak, MS, MSc Genetic Counselor Hereditary Cancer Clinic

Jocelyn Chapman, MD Division of Gynecologic Oncology. Julie S. Mak, MS, MSc Genetic Counselor Hereditary Cancer Clinic Jocelyn Chapman, MD Division of Gynecologic Oncology Julie S. Mak, MS, MSc Genetic Counselor Hereditary Cancer Clinic Genetics underlies all cancers Somatic or tumor genetics Germline or inherited genetics

More information

SUPPLEMENTARY INFORMATION

SUPPLEMENTARY INFORMATION Supplementary Information S1 Frequency of DNMT3A mutations in hematologic disorders and their associated clinical phenotypes. Disease Patient population Frequency (%) Associated Clinical Characteristics

More information

The Next Generation of Hereditary Cancer Testing

The Next Generation of Hereditary Cancer Testing The Next Generation of Hereditary Cancer Testing Why Genetic Testing? Cancers can appear to run in families. Often this is due to shared environmental or lifestyle patterns, such as tobacco use. However,

More information

Addressing the challenges of genomic characterization of hematologic malignancies using microarrays

Addressing the challenges of genomic characterization of hematologic malignancies using microarrays Addressing the challenges of genomic characterization of hematologic malignancies using microarrays Sarah South, PhD, FACMG Medical Director, ARUP Laboratories Department of Pediatrics and Pathology University

More information

Time Matters. Results Count! Company Overview Presentation. August Improving Patient Care through exceptional cancer genetic testing services!

Time Matters. Results Count! Company Overview Presentation. August Improving Patient Care through exceptional cancer genetic testing services! Time Matters. Results Count! Company Overview Presentation August 2014 Improving Patient Care through exceptional cancer genetic testing services! Forward-looking Statements This presentation contains

More information

7/12/2016 TESTING. Objectives. New Directions in Aplastic Anemia: What's on the Horizon? Better way to evaluate clonal evolution?

7/12/2016 TESTING. Objectives. New Directions in Aplastic Anemia: What's on the Horizon? Better way to evaluate clonal evolution? New Directions in Aplastic Anemia: What's on the Horizon? Amy E. DeZern, MD; MHS Assistant Professor Hematologic Malignancies Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Baltimore, MD Objectives

More information

Molecular profiling in confirming the diagnosis of early myelodysplastic syndrome

Molecular profiling in confirming the diagnosis of early myelodysplastic syndrome Molecular profiling of early MDS Hematopathology - March 2016 Article Molecular profiling in confirming the diagnosis of early myelodysplastic syndrome Maya Thangavelu 1,*, Ryan Olson 2, Li Li 2, Wanlong

More information

We are in an era that promises a rational. treatment of cancer patients. Levy et al. Genome Research 22:2201, 2012 Vanderbilt university

We are in an era that promises a rational. treatment of cancer patients. Levy et al. Genome Research 22:2201, 2012 Vanderbilt university Enhancing Assessment of Leukemia with Next Generation Sequencing Michelle Afkhami, M.D. Medical Director, Clinical i l Molecular l Laboratory City of Hope National Medical Center How the Expert Treat Hematologic

More information

Objectives. Morphology and IHC. Flow and Cyto FISH. Testing for Heme Malignancies 3/20/2013

Objectives. Morphology and IHC. Flow and Cyto FISH. Testing for Heme Malignancies 3/20/2013 Molecular Markers in Hematologic Malignancy: Ways to locate the needle in the haystack. Objectives Review the types of testing for hematologic malignancies Understand rationale for molecular testing Marcie

More information

Cost-Effective Strategies in the Workup of Hematologic Neoplasm. Karl S. Theil, Claudiu V. Cotta Cleveland Clinic

Cost-Effective Strategies in the Workup of Hematologic Neoplasm. Karl S. Theil, Claudiu V. Cotta Cleveland Clinic Cost-Effective Strategies in the Workup of Hematologic Neoplasm Karl S. Theil, Claudiu V. Cotta Cleveland Clinic In the past 12 months, we have not had a significant financial interest or other relationship

More information

Challenges and Opportunities for Digital PCR in the Cancer CLIA Laboratory The Moffitt Cancer Center Experience

Challenges and Opportunities for Digital PCR in the Cancer CLIA Laboratory The Moffitt Cancer Center Experience Challenges and Opportunities for Digital PCR in the Cancer CLIA Laboratory The Moffitt Cancer Center Experience Anthony M Magliocco MD FRCPC FCAP Chair of Anatomic Pathology & Executive Director Esoteric

More information

What is the status of the technologies of "precision medicine?

What is the status of the technologies of precision medicine? Session 2: What is the status of the technologies of "precision medicine? Gideon Blumenthal, MD, Clinical Team Leader, Thoracic and Head/Neck Oncology, Center for Drug Evaluation and Research (CDER), U.S.

More information

Secuenciación masiva: papel en la toma de decisiones

Secuenciación masiva: papel en la toma de decisiones Secuenciación masiva: papel en la toma de decisiones Cancer is a Genetic Disease Development of cancer is driven by the acquisition of somatic genetic alterations: Nonsynonymous point mutations: missense.

More information

Implementation of nation-wide molecular testing in oncology in the French Health care system : quality assurance issues & challenges

Implementation of nation-wide molecular testing in oncology in the French Health care system : quality assurance issues & challenges Implementation of nation-wide molecular testing in oncology in the French Health care system : quality assurance issues & challenges Frédérique Nowak - 21 october 2015 "Putting Science into Standards event:

More information

Detecting Oncogenic Mutations in Whole Blood

Detecting Oncogenic Mutations in Whole Blood WHITE PAPER Detecting Oncogenic Mutations in Whole Blood Analytical validation of Cynvenio Biosystems LiquidBiopsy circulating tumor cell (CTC) capture and next-generation sequencing (NGS) September 2013

More information

Prior Authorization Required: Additional Information:

Prior Authorization Required: Additional Information: Genetic Testing for Somatic Tumor Markers MP9486 Covered Service: Prior Authorization Required: Additional Information: Yes when meets criteria below No A first-degree relative is defined as an individual

More information

Acute Myeloid Leukemia with RUNX1 and Several Co-mutations

Acute Myeloid Leukemia with RUNX1 and Several Co-mutations Case SH2017-0281 Acute Myeloid Leukemia with RUNX1 and Several Co-mutations James Bauer, MD, PhD David Yang, MD Erik Ranheim, MD, PhD Catherine Leith, MB, Bchir Clinical History Chief Complaint: 72 year

More information

A guide to genetic testing for hereditary cancers

A guide to genetic testing for hereditary cancers Cancer Testing Solutions A guide to genetic testing for hereditary cancers The benefit of knowing TM Hereditary cancer genetic testing can play a critical role in managing health Cancer touches millions

More information

SUPPLEMENTARY INFORMATION

SUPPLEMENTARY INFORMATION doi:10.1038/nature13898 Supplementary Information Table 1 Kras mutation status of carcinogen-induced mouse lung adenomas Tumour Treatment Strain Grade Genotype Kras status (WES)* Kras status (Sanger) 32T1

More information

Objectives and Financial Disclosure

Objectives and Financial Disclosure Enhancing Assessment of Leukemia and Lymphoma with Next Generation Sequencing Michelle Afkhami, M.D. Medical Director, Clinical Molecular Laboratory Assistant Professor, Department of Pathology City of

More information

DISCLOSURE Luca Malcovati, MD. No financial relationships to disclose

DISCLOSURE Luca Malcovati, MD. No financial relationships to disclose ICUS, CCUS and CHIP Luca Malcovati, MD Department of Molecular Medicine, University of Pavia Medical School, & Department of Hematology Oncology, IRCCS Policlinico S. Matteo Foundation, Pavia, Italy DISCLOSURE

More information

Transform genomic data into real-life results

Transform genomic data into real-life results CLINICAL SUMMARY Transform genomic data into real-life results Biomarker testing and targeted therapies can drive improved outcomes in clinical practice New FDA-Approved Broad Companion Diagnostic for

More information

Molecular Genetics of Paediatric Tumours. Gino Somers MBBS, BMedSci, PhD, FRCPA Pathologist-in-Chief Hospital for Sick Children, Toronto, ON, CANADA

Molecular Genetics of Paediatric Tumours. Gino Somers MBBS, BMedSci, PhD, FRCPA Pathologist-in-Chief Hospital for Sick Children, Toronto, ON, CANADA Molecular Genetics of Paediatric Tumours Gino Somers MBBS, BMedSci, PhD, FRCPA Pathologist-in-Chief Hospital for Sick Children, Toronto, ON, CANADA Financial Disclosure NanoString - conference costs for

More information

Matthew Smolkin, MD HCLD Medical Director Molecular Pathology Diagnostic Laboratory

Matthew Smolkin, MD HCLD Medical Director Molecular Pathology Diagnostic Laboratory Molecular Profiling Matthew Smolkin, MD HCLD Medical Director Molecular Pathology Diagnostic Laboratory Objectives Defining molecular profiling Technologies Why do we profile tumors? Current testing &

More information

Provide your cancer patients personalized treatment options with ClariFind

Provide your cancer patients personalized treatment options with ClariFind ONCOLOGY ClariFind employs next-generation sequencing (NGS) for comprehensive genomic profiling of a patient s tumor sample to identify potential clinically actionable targets and associated therapies.

More information

EXT ADDRESS CITY LAST NAME ID NUMBER PT. ADDRESS CITY INSURANCE PROVIDER. 0 Other. 0 IGH/B-cell cionaliry (PCR)

EXT ADDRESS CITY LAST NAME ID NUMBER PT. ADDRESS CITY INSURANCE PROVIDER. 0 Other. 0 IGH/B-cell cionaliry (PCR) THE UNIVERSITY OF TEXAS *Required Fields PHYSICIAN! FACILITY/ CLIENT INFORMATION MDAndersonefief &ter MaltgararEettcy 'REQUESTING PHYSICIAN Division of Pathology! Laboratory Medicine Services Test Requisition

More information

Molecular Markers. Marcie Riches, MD, MS Associate Professor University of North Carolina Scientific Director, Infection and Immune Reconstitution WC

Molecular Markers. Marcie Riches, MD, MS Associate Professor University of North Carolina Scientific Director, Infection and Immune Reconstitution WC Molecular Markers Marcie Riches, MD, MS Associate Professor University of North Carolina Scientific Director, Infection and Immune Reconstitution WC Overview Testing methods Rationale for molecular testing

More information

Hematology Fusion/Expression Profile

Hematology Fusion/Expression Profile Hematology Fusion/Expression Profile Patient Name: Ordered By Date of Birth: Ordering Physician: Gender (M/F): Physician ID: Client: Accession #: Case #: Specimen Type: Body Site: Specimen ID: Ethnicity:

More information

6/12/2018. Disclosures. Clinical Genomics The CLIA Lab Perspective. Outline. COH HopeSeq Heme Panels

6/12/2018. Disclosures. Clinical Genomics The CLIA Lab Perspective. Outline. COH HopeSeq Heme Panels Clinical Genomics The CLIA Lab Perspective Disclosures Raju K. Pillai, M.D. Hematopathologist / Molecular Pathologist Director, Pathology Bioinformatics City of Hope National Medical Center, Duarte, CA

More information

Enterprise Interest Thermo Fisher Scientific / Employee

Enterprise Interest Thermo Fisher Scientific / Employee Enterprise Interest Thermo Fisher Scientific / Employee A next-generation sequencing assay to estimate tumor mutation load from FFPE research samples Fiona Hyland. Director of R&D, Bioinformatics Clinical

More information

MOLECULAR SERVICES. mlabs.umich.edu

MOLECULAR SERVICES. mlabs.umich.edu MOLECULAR SERVICES mlabs.umich.edu 800.862.7284 PICTURED ON LEFT IS MARWAN TAYEH, PH.D, CLINICAL ASSISTANT PROFESSOR, PEDIATRICS - GENETICS, ON RIGHT IS TODD ACKLEY, LABORATORY MANAGER MLabs is a full-service

More information